Most Common Causes of Death in Multiple Myeloma
Infections are the leading cause of death in patients with multiple myeloma, followed by disease progression itself, with cardiovascular events and renal complications also contributing significantly to mortality. 1
Primary Causes of Death
Infection (Leading Cause)
- Infections represent the most common cause of death in myeloma patients 1
- Bacterial and viral infections, particularly pneumonia and sepsis, occur most frequently during the first few months of induction therapy 2
- T cell immune dysfunction and hypogammaglobulinemia from B cell compartment changes increase susceptibility 1
- In early mortality cohorts (deaths within 12 months), infection accounts for approximately 62.5% of deaths 3
Disease Progression (Second Leading Cause)
- Myeloma progression itself causes 43.2% of deaths in the first year 2
- Overall, MM-specific death accounts for 74% of deaths in transplant-eligible patients and 67% in non-transplant patients 4
- Despite therapeutic advances, myeloma remains the greatest threat to overall survival 4
Cardiovascular Events
- Cardiac-associated events (heart failure, cardiac amyloidosis) account for 14.4% of deaths 2
- MM patients have twice the risk of cardiovascular death compared to the general population (SMR = 2.01) 5
- Sudden death accounts for 7.5% of mortality 2
Secondary Malignancies
- Second primary cancers are the second leading cause of death after MM itself 4
- MM patients have nearly twice the risk of dying from non-myeloma malignancies compared to the general population (SMR = 1.97) 5
Renal Complications
- Renal failure contributes to early mortality, particularly in patients with renal impairment at diagnosis 6
Temporal Patterns and Risk Factors
Early mortality (within first year) deserves particular attention:
- 31.7% of all deaths occur within the first year of treatment 2
- Risk factors for early death include:
Clinical Implications
Proactive infection prevention is critical, especially during the first 12 weeks of induction therapy when bacterial and viral infections peak 1, 2. Prophylactic levofloxacin during initial treatment reduces febrile episodes and death (HR 0.66) 1.
Comprehensive cardiac evaluation should be performed in elderly patients with elevated inflammatory markers or poor performance status, given the substantial cardiovascular mortality risk 2, 5.
Late mortality remains a concern even as survival improves, with cardiovascular events and second malignancies requiring increased surveillance in long-term survivors 5.